Policy & Regulation
Rgenix Raises USD 40m in Series C Funding To Support Clinical Stage Oncology Programs
11 October 2018 - - US-based biopharmaceutical company Rgenix, Inc has raised USD 40m in a Series C financing in support of further development of the company's clinical and pre-clinical oncology programs and for general corporate purposes, the company said.

The Series C financing was led by Lepu Medical, a publicly traded global healthcare firm, and includes Oceanpine Capital and WuXi AppTec's Corporate Venture Fund.

Existing investors also participated in the financing round, including Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments, LLC, and the Partnership Fund for New York City's Innovate NY Fund and associated entities.

The financing will support Phase 1b/2 clinical trials of the lead program RGX-104 in multiple cancer indications, including in checkpoint inhibitor refractory patients.

It will also support early clinical development of RGX-202, a first-in-class cancer metabolism programme, as well as discovery stage programs arising from the Rgenix target discovery platform.

RGX-104 is a first-in-class small-molecule immunotherapy that targets the Liver X Receptor and modulates innate immunity by activating the ApoE gene. Data from a Phase 1a dose escalation of RGX-104 in advanced cancer patients demonstrated both immune-stimulatory and anti-tumor activity.

Rgenix is currently enrolling patients in the Phase 1b stage of the trial in multiple cancer indications, including in combination with the checkpoint inhibitor nivolumab.

RGX-202 is a small molecule compound that suppresses gastrointestinal cancer progression by inhibiting a novel cancer metabolism pathway involved in supplying energy to cancer cells.

Pre-clinical research shows the compound is active as a monotherapy and in combination with chemotherapy considered to be the standard of care. Rgenix expects to launch a Phase 1 trial of RGX-202 in 2018.

Rgenix was advised by Jefferies LLC in this Series C financing.

Rgenix is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression.

The company said it is pursuing several first-in-class drug candidates to treat cancers of high unmet need. Rgenix identifies novel cancer targets using a microRNA based target discovery platform originally developed by Rgenix's scientific co-founders at The Rockefeller University and now exclusively licensed to Rgenix.

Rgenix brings together distinguished scientific founders, a seasoned Board, and a leadership team comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Ltd., Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments,LLC, and the Partnership Fund for New York City.